DIVISLAB2021-10-012021-12-31in-bse-fin:OneOperatingExpenses01Member DIVISLAB2021-10-012021-12-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares DIVISLAB 2021-04-01 2022-03-31 2022-02-01 INR Lakhs Third quarter Single segment Pharmaceuticals 2021-10-01 2021-12-31 Unaudited Standalone 24667700000.00 166200000.00 24833900000.00 8850800000.00 0.00 -590800000.00 2397200000.00 2000000.00 797000000.00 3011500000.00 14467700000.00 10366200000.00 0.00 10366200000.00 1192000000.00 102000000.00 1294000000.00 0.00 9072200000.00 0.00 0.00 0.00 0.00 9072200000.00 500000.00 9072700000.00 9072700000.00 0.00 530900000.00 2 34.17 34.17 0.00 0.00 34.17 34.17 1.The above Statement of standalone unaudited financial results for the quarter and nine months ended 31st December, 2021, is prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under section 133 of the Companies Act 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The financial results were, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 11th February, 2022. The same also were subjected to “limited review” by the Auditors of the Company and their report contains no qualification. 2.The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reportable business segment as per Ind AS 108. 3.The Company does not have any discontinued operations and the Profit for the period represents the Profits from continuing operations only. 4.The Company has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. As the pandemic continues to evolve, the Company will continue to closely monitor for any material changes to future economic conditions. 5.Forex gain included in Other Income and Loss included in Other Expenses for the respective periods is as given below: Rs. in lakhs Quarter ended Nine Months ended Year ended 31.12.2021 30.09.2021 31.12.2020 31.12.2021 31.12.2020 31.03.2021 Forex gain/(loss) (362) (691) 289 869 (404) (77) 6.Figures for the previous year/period have been reclassified/ regrouped wherever necessary to conform to current period’s classification. Single segment 2021-04-01 2021-12-31 Unaudited Standalone 63847900000.00 607500000.00 64455400000.00 25113600000.00 0.00 -3904600000.00 6750600000.00 6100000.00 2298000000.00 8083400000.00 38347100000.00 26108300000.00 0.00 26108300000.00 4925100000.00 527400000.00 5452500000.00 0.00 20655800000.00 0.00 0.00 0.00 0.00 20655800000.00 1300000.00 20657100000.00 20657100000.00 0.00 530900000.00 2 77.81 77.81 0.00 0.00 77.81 77.81 Others 3011500000.00 Others 8083400000.00